3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Conditions
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Ovarian Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Urinary Bladder Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Head and Neck Neoplasms
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Interventions
Bevacizumab
234
Fluorouracil
220
Oxaliplatin
216
Irinotecan
215
Leucovorin
199
Capecitabine
153
Cetuximab
146
Panitumumab
70
Folfox protocol
51
regorafenib
43
Radiotherapy
38
pembrolizumab
37
IFL protocol
36
HMPL-013
36
trifluridine tipiracil drug combination
32
Nivolumab
32
Drug Therapy
26
Neoadjuvant Therapy
24
Trifluridine
18
Celecoxib
18
tislelizumab
17
XELOX
17
sintilimab
16
Trastuzumab
16
durvalumab
15
atezolizumab
15
aflibercept
15
Chemotherapy, Adjuvant
15
Biopsy
15
apatinib
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Colorectal Neoplasms
×
tisotumab vedotin
×
Clear all
NCT03485209
2026-04-20
innovaTV 207
Seagen Inc.
Phase 2
Active not recruiting
350 enrolled